AbbVie Stock Surges 9.34% in Four Days as Q1 Revenues Hit $13.343 Billion

AbbVie (ABBV) shares rose 3.15% on April 25, 2025, marking the fourth consecutive day of gains, with a total increase of 9.34% over the past four days. The company's strong performance was driven by robust financial results for the first quarter of 2025.

AbbVie reported first-quarter 2025 net revenues of $13.343 billion, an 8.4% increase on a reported basis, or 9.8% on an operational basis. The company's adjusted earnings per share (EPS) for the quarter were $2.46, surpassing the consensus estimate of $2.39. This strong performance led to an upward revision of the full-year adjusted EPS forecast to a range of $12.09 to $12.29, up from the previous guidance of $11.99 to $12.19.

The company's immunology portfolio saw significant growth, with revenues increasing by 16.6% to $6.26 billion. Key products such as Skyrizi and Rinvoq experienced substantial sales increases of 70.5% and 57.2%, respectively. However, Humira sales declined by 50.6%, reflecting the continued impact of the loss of exclusivity in the US market.

AbbVie's CEO, Robert Michael, highlighted the company's strong fundamentals and strategic investments, which position AbbVie for long-term success. The company's pipeline advancements and strategic investments continue to bolster its outlook, contributing to the positive market sentiment and driving the stock's recent gains.